A multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of SYR-322 compared with placebo in subjects with type 2 diabetes.
Phase of Trial: Phase III
Latest Information Update: 28 Aug 2014
At a glance
- Drugs Alogliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 31 Aug 2018 Biomarkers information updated
- 18 Dec 2008 Status changed from active, no longer recruiting to completed, according to clinicaltrials.gov.
- 01 Dec 2008 Results published in Diabetes Care.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History